228 related articles for article (PubMed ID: 37452026)
1. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.
El-Botty R; Morriset L; Montaudon E; Tariq Z; Schnitzler A; Bacci M; Lorito N; Sourd L; Huguet L; Dahmani A; Painsec P; Derrien H; Vacher S; Masliah-Planchon J; Raynal V; Baulande S; Larcher T; Vincent-Salomon A; Dutertre G; Cottu P; Gentric G; Mechta-Grigoriou F; Hutton S; Driouch K; Bièche I; Morandi A; Marangoni E
Nat Commun; 2023 Jul; 14(1):4221. PubMed ID: 37452026
[TBL] [Abstract][Full Text] [Related]
2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
3. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW; Yuca E; Scott SS; Zhao M; Paez Arango N; Cruz Pico CX; Saridogan T; Shariati M; Class CA; Bristow CA; Vellano CP; Zheng X; Gonzalez-Angulo AM; Su X; Tapia C; Chen K; Akcakanat A; Lim B; Tripathy D; Yap TA; Francesco MED; Draetta GF; Jones P; Heffernan TP; Marszalek JR; Meric-Bernstam F
Cancer Res; 2021 Nov; 81(21):5572-5581. PubMed ID: 34518211
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
5. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
6. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Kettner NM; Vijayaraghavan S; Durak MG; Bui T; Kohansal M; Ha MJ; Liu B; Rao X; Wang J; Yi M; Carey JPW; Chen X; Eckols TK; Raghavendra AS; Ibrahim NK; Karuturi MS; Watowich SS; Sahin A; Tweardy DJ; Hunt KK; Tripathy D; Keyomarsi K
Clin Cancer Res; 2019 Jul; 25(13):3996-4013. PubMed ID: 30867218
[TBL] [Abstract][Full Text] [Related]
8. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
[No Abstract] [Full Text] [Related]
9. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Montaudon E; Nikitorowicz-Buniak J; Sourd L; Morisset L; El Botty R; Huguet L; Dahmani A; Painsec P; Nemati F; Vacher S; Chemlali W; Masliah-Planchon J; Château-Joubert S; Rega C; Leal MF; Simigdala N; Pancholi S; Ribas R; Nicolas A; Meseure D; Vincent-Salomon A; Reyes C; Rapinat A; Gentien D; Larcher T; Bohec M; Baulande S; Bernard V; Decaudin D; Coussy F; Le Romancer M; Dutertre G; Tariq Z; Cottu P; Driouch K; Bièche I; Martin LA; Marangoni E
Nat Commun; 2020 Aug; 11(1):4053. PubMed ID: 32792481
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Shariati M; Evans KW; Zheng X; Bristow CA; Ng PK; Rizvi YQ; Tapia C; Yang F; Carugo A; Heffernan TP; Peoples MD; Tripathy D; Meric-Bernstam F
Oncogene; 2021 Jul; 40(26):4425-4439. PubMed ID: 34108622
[TBL] [Abstract][Full Text] [Related]
11. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
12. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Sansone P; Ceccarelli C; Berishaj M; Chang Q; Rajasekhar VK; Perna F; Bowman RL; Vidone M; Daly L; Nnoli J; Santini D; Taffurelli M; Shih NN; Feldman M; Mao JJ; Colameco C; Chen J; DeMichele A; Fabbri N; Healey JH; Cricca M; Gasparre G; Lyden D; Bonafé M; Bromberg J
Nat Commun; 2016 Feb; 7():10442. PubMed ID: 26858125
[TBL] [Abstract][Full Text] [Related]
13. S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.
Mo H; Liu X; Xue Y; Chen H; Guo S; Li Z; Wang S; Li C; Han J; Fu M; Song Y; Li D; Ma F
Mol Cancer; 2022 Aug; 21(1):171. PubMed ID: 36042494
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
15. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
Ono M; Oba T; Shibata T; Ito KI
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3211-3224. PubMed ID: 34244855
[TBL] [Abstract][Full Text] [Related]
16. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
17. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
Scherer SD; Riggio AI; Haroun F; DeRose YS; Ekiz HA; Fujita M; Toner J; Zhao L; Li Z; Oesterreich S; Samatar AA; Welm AL
Breast Cancer Res; 2021 Oct; 23(1):100. PubMed ID: 34717714
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells.
Lanceta L; O'Neill C; Lypova N; Li X; Rouchka E; Waigel S; Gomez-Gutierrez JG; Chesney J; Imbert-Fernandez Y
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344635
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
